Abstract
Abatacept is a non-TNF biologic DMARD controlling T-cell costimulation in the antigen presentation of immunoreaction. Abatacept has an influence on the cell expressing CD80/CD86. Recently, it is suggested that abatacept is involved in the decrease of an antigen presenting cell and the differentiation of osteoclast. Its efficacy and safety are shown to be equal to adalimumab in a direct competitive trial and are recommended as a first-line drug of biologic DMARDs in a variety of guidelines. However, the maintenance of the remission after the abatacept cancellation is difficult like other biologic DMARDs. Some studies showed a suppressive effect of the ACPA production about etiology of the rheumatoid arthritis, but the clear conclusion is not provided, so the further examinations are remained in the future.
